Global RNA Interference (RNAi)-Based Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global RNA Interference (RNAi)-Based Therapeutics market size was valued at USD 1035.6 million in 2022 and is forecast to a readjusted size of USD 5308.7 million by 2029 with a CAGR of 26.3% during review period.
The Small Interfering RNA (siRNA) Drugs Market is driven by the transformative potential of siRNA-based therapies in silencing disease-associated genes, making them a promising approach for treating a wide range of diseases, including genetic disorders, viral infections, and various cancers. siRNA drugs work by selectively degrading or inhibiting the expression of specific genes, offering a highly targeted and personalized treatment option. As the understanding of genomics and RNA interference mechanisms advances, and the need for precision medicine grows, the demand for siRNA drugs continues to rise. Innovations in siRNA design, delivery systems, and gene-editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to overcome delivery barriers, ensure the stability and safety of siRNA therapeutics, and navigate regulatory complexities. Addressing off-target effects, optimizing pharmacokinetics, and managing the high cost of siRNA drug development are ongoing challenges. Additionally, the market faces competition from traditional therapeutic approaches and the need for continuous research and development to unlock the full therapeutic potential of siRNA drugs. Striking a balance between providing safe, effective, and accessible siRNA therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Small Interfering RNA (siRNA) Drugs Market.
The Global Info Research report includes an overview of the development of the RNA Interference (RNAi)-Based Therapeutics industry chain, the market status of AHP (siRNA, miRNA), hATTR (siRNA, miRNA), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of RNA Interference (RNAi)-Based Therapeutics.
Regionally, the report analyzes the RNA Interference (RNAi)-Based Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global RNA Interference (RNAi)-Based Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the RNA Interference (RNAi)-Based Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the RNA Interference (RNAi)-Based Therapeutics industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., siRNA, miRNA).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the RNA Interference (RNAi)-Based Therapeutics market.
Regional Analysis: The report involves examining the RNA Interference (RNAi)-Based Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the RNA Interference (RNAi)-Based Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to RNA Interference (RNAi)-Based Therapeutics:
Company Analysis: Report covers individual RNA Interference (RNAi)-Based Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards RNA Interference (RNAi)-Based Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (AHP, hATTR).
Technology Analysis: Report covers specific technologies relevant to RNA Interference (RNAi)-Based Therapeutics. It assesses the current state, advancements, and potential future developments in RNA Interference (RNAi)-Based Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the RNA Interference (RNAi)-Based Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
RNA Interference (RNAi)-Based Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe RNA Interference (RNAi)-Based Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNA Interference (RNAi)-Based Therapeutics, with revenue, gross margin and global market share of RNA Interference (RNAi)-Based Therapeutics from 2018 to 2023.
Chapter 3, the RNA Interference (RNAi)-Based Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and RNA Interference (RNAi)-Based Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNA Interference (RNAi)-Based Therapeutics.
Chapter 13, to describe RNA Interference (RNAi)-Based Therapeutics research findings and conclusion.
The Small Interfering RNA (siRNA) Drugs Market is driven by the transformative potential of siRNA-based therapies in silencing disease-associated genes, making them a promising approach for treating a wide range of diseases, including genetic disorders, viral infections, and various cancers. siRNA drugs work by selectively degrading or inhibiting the expression of specific genes, offering a highly targeted and personalized treatment option. As the understanding of genomics and RNA interference mechanisms advances, and the need for precision medicine grows, the demand for siRNA drugs continues to rise. Innovations in siRNA design, delivery systems, and gene-editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to overcome delivery barriers, ensure the stability and safety of siRNA therapeutics, and navigate regulatory complexities. Addressing off-target effects, optimizing pharmacokinetics, and managing the high cost of siRNA drug development are ongoing challenges. Additionally, the market faces competition from traditional therapeutic approaches and the need for continuous research and development to unlock the full therapeutic potential of siRNA drugs. Striking a balance between providing safe, effective, and accessible siRNA therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Small Interfering RNA (siRNA) Drugs Market.
The Global Info Research report includes an overview of the development of the RNA Interference (RNAi)-Based Therapeutics industry chain, the market status of AHP (siRNA, miRNA), hATTR (siRNA, miRNA), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of RNA Interference (RNAi)-Based Therapeutics.
Regionally, the report analyzes the RNA Interference (RNAi)-Based Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global RNA Interference (RNAi)-Based Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the RNA Interference (RNAi)-Based Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the RNA Interference (RNAi)-Based Therapeutics industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., siRNA, miRNA).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the RNA Interference (RNAi)-Based Therapeutics market.
Regional Analysis: The report involves examining the RNA Interference (RNAi)-Based Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the RNA Interference (RNAi)-Based Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to RNA Interference (RNAi)-Based Therapeutics:
Company Analysis: Report covers individual RNA Interference (RNAi)-Based Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards RNA Interference (RNAi)-Based Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (AHP, hATTR).
Technology Analysis: Report covers specific technologies relevant to RNA Interference (RNAi)-Based Therapeutics. It assesses the current state, advancements, and potential future developments in RNA Interference (RNAi)-Based Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the RNA Interference (RNAi)-Based Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
RNA Interference (RNAi)-Based Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- siRNA
- miRNA
- shRNA
- AHP
- hATTR
- Other
- Alnylam
- Novartis
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe RNA Interference (RNAi)-Based Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNA Interference (RNAi)-Based Therapeutics, with revenue, gross margin and global market share of RNA Interference (RNAi)-Based Therapeutics from 2018 to 2023.
Chapter 3, the RNA Interference (RNAi)-Based Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and RNA Interference (RNAi)-Based Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNA Interference (RNAi)-Based Therapeutics.
Chapter 13, to describe RNA Interference (RNAi)-Based Therapeutics research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of RNA Interference (RNAi)-Based Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RNA Interference (RNAi)-Based Therapeutics by Type
1.3.1 Overview: Global RNA Interference (RNAi)-Based Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 siRNA
1.3.4 miRNA
1.3.5 shRNA
1.4 Global RNA Interference (RNAi)-Based Therapeutics Market by Application
1.4.1 Overview: Global RNA Interference (RNAi)-Based Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 AHP
1.4.3 hATTR
1.4.4 Other
1.5 Global RNA Interference (RNAi)-Based Therapeutics Market Size & Forecast
1.6 Global RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast by Region
1.6.1 Global RNA Interference (RNAi)-Based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global RNA Interference (RNAi)-Based Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Alnylam
2.1.1 Alnylam Details
2.1.2 Alnylam Major Business
2.1.3 Alnylam RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.1.4 Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Alnylam Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.2.4 Novartis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Sylentis
2.3.1 Sylentis Details
2.3.2 Sylentis Major Business
2.3.3 Sylentis RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.3.4 Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Sylentis Recent Developments and Future Plans
2.4 Arrowhead
2.4.1 Arrowhead Details
2.4.2 Arrowhead Major Business
2.4.3 Arrowhead RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.4.4 Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Arrowhead Recent Developments and Future Plans
2.5 Silence Therapeutics
2.5.1 Silence Therapeutics Details
2.5.2 Silence Therapeutics Major Business
2.5.3 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.5.4 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Silence Therapeutics Recent Developments and Future Plans
2.6 Dicerna
2.6.1 Dicerna Details
2.6.2 Dicerna Major Business
2.6.3 Dicerna RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.6.4 Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Dicerna Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global RNA Interference (RNAi)-Based Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of RNA Interference (RNAi)-Based Therapeutics by Company Revenue
3.2.2 Top 3 RNA Interference (RNAi)-Based Therapeutics Players Market Share in 2022
3.2.3 Top 6 RNA Interference (RNAi)-Based Therapeutics Players Market Share in 2022
3.3 RNA Interference (RNAi)-Based Therapeutics Market: Overall Company Footprint Analysis
3.3.1 RNA Interference (RNAi)-Based Therapeutics Market: Region Footprint
3.3.2 RNA Interference (RNAi)-Based Therapeutics Market: Company Product Type Footprint
3.3.3 RNA Interference (RNAi)-Based Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global RNA Interference (RNAi)-Based Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global RNA Interference (RNAi)-Based Therapeutics Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global RNA Interference (RNAi)-Based Therapeutics Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
6.2 North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
6.3 North America RNA Interference (RNAi)-Based Therapeutics Market Size by Country
6.3.1 North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Country
7.3.1 Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Market Size by Region
8.3.1 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
9.2 South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
9.3 South America RNA Interference (RNAi)-Based Therapeutics Market Size by Country
9.3.1 South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Country
10.3.1 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 RNA Interference (RNAi)-Based Therapeutics Market Drivers
11.2 RNA Interference (RNAi)-Based Therapeutics Market Restraints
11.3 RNA Interference (RNAi)-Based Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 RNA Interference (RNAi)-Based Therapeutics Industry Chain
12.2 RNA Interference (RNAi)-Based Therapeutics Upstream Analysis
12.3 RNA Interference (RNAi)-Based Therapeutics Midstream Analysis
12.4 RNA Interference (RNAi)-Based Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of RNA Interference (RNAi)-Based Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RNA Interference (RNAi)-Based Therapeutics by Type
1.3.1 Overview: Global RNA Interference (RNAi)-Based Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 siRNA
1.3.4 miRNA
1.3.5 shRNA
1.4 Global RNA Interference (RNAi)-Based Therapeutics Market by Application
1.4.1 Overview: Global RNA Interference (RNAi)-Based Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 AHP
1.4.3 hATTR
1.4.4 Other
1.5 Global RNA Interference (RNAi)-Based Therapeutics Market Size & Forecast
1.6 Global RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast by Region
1.6.1 Global RNA Interference (RNAi)-Based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global RNA Interference (RNAi)-Based Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Alnylam
2.1.1 Alnylam Details
2.1.2 Alnylam Major Business
2.1.3 Alnylam RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.1.4 Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Alnylam Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.2.4 Novartis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Sylentis
2.3.1 Sylentis Details
2.3.2 Sylentis Major Business
2.3.3 Sylentis RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.3.4 Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Sylentis Recent Developments and Future Plans
2.4 Arrowhead
2.4.1 Arrowhead Details
2.4.2 Arrowhead Major Business
2.4.3 Arrowhead RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.4.4 Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Arrowhead Recent Developments and Future Plans
2.5 Silence Therapeutics
2.5.1 Silence Therapeutics Details
2.5.2 Silence Therapeutics Major Business
2.5.3 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.5.4 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Silence Therapeutics Recent Developments and Future Plans
2.6 Dicerna
2.6.1 Dicerna Details
2.6.2 Dicerna Major Business
2.6.3 Dicerna RNA Interference (RNAi)-Based Therapeutics Product and Solutions
2.6.4 Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Dicerna Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global RNA Interference (RNAi)-Based Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of RNA Interference (RNAi)-Based Therapeutics by Company Revenue
3.2.2 Top 3 RNA Interference (RNAi)-Based Therapeutics Players Market Share in 2022
3.2.3 Top 6 RNA Interference (RNAi)-Based Therapeutics Players Market Share in 2022
3.3 RNA Interference (RNAi)-Based Therapeutics Market: Overall Company Footprint Analysis
3.3.1 RNA Interference (RNAi)-Based Therapeutics Market: Region Footprint
3.3.2 RNA Interference (RNAi)-Based Therapeutics Market: Company Product Type Footprint
3.3.3 RNA Interference (RNAi)-Based Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global RNA Interference (RNAi)-Based Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global RNA Interference (RNAi)-Based Therapeutics Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global RNA Interference (RNAi)-Based Therapeutics Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
6.2 North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
6.3 North America RNA Interference (RNAi)-Based Therapeutics Market Size by Country
6.3.1 North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Country
7.3.1 Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Market Size by Region
8.3.1 Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
9.2 South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
9.3 South America RNA Interference (RNAi)-Based Therapeutics Market Size by Country
9.3.1 South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Country
10.3.1 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE RNA Interference (RNAi)-Based Therapeutics Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 RNA Interference (RNAi)-Based Therapeutics Market Drivers
11.2 RNA Interference (RNAi)-Based Therapeutics Market Restraints
11.3 RNA Interference (RNAi)-Based Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 RNA Interference (RNAi)-Based Therapeutics Industry Chain
12.2 RNA Interference (RNAi)-Based Therapeutics Upstream Analysis
12.3 RNA Interference (RNAi)-Based Therapeutics Midstream Analysis
12.4 RNA Interference (RNAi)-Based Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Alnylam Company Information, Head Office, and Major Competitors
Table 6. Alnylam Major Business
Table 7. Alnylam RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 8. Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Alnylam Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 13. Novartis RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Sylentis Company Information, Head Office, and Major Competitors
Table 16. Sylentis Major Business
Table 17. Sylentis RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 18. Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Sylentis Recent Developments and Future Plans
Table 20. Arrowhead Company Information, Head Office, and Major Competitors
Table 21. Arrowhead Major Business
Table 22. Arrowhead RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 23. Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Arrowhead Recent Developments and Future Plans
Table 25. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 26. Silence Therapeutics Major Business
Table 27. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 28. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Silence Therapeutics Recent Developments and Future Plans
Table 30. Dicerna Company Information, Head Office, and Major Competitors
Table 31. Dicerna Major Business
Table 32. Dicerna RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 33. Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Dicerna Recent Developments and Future Plans
Table 35. Global RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 36. Global RNA Interference (RNAi)-Based Therapeutics Revenue Share by Players (2018-2023)
Table 37. Breakdown of RNA Interference (RNAi)-Based Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 38. Market Position of Players in RNA Interference (RNAi)-Based Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 39. Head Office of Key RNA Interference (RNAi)-Based Therapeutics Players
Table 40. RNA Interference (RNAi)-Based Therapeutics Market: Company Product Type Footprint
Table 41. RNA Interference (RNAi)-Based Therapeutics Market: Company Product Application Footprint
Table 42. RNA Interference (RNAi)-Based Therapeutics New Market Entrants and Barriers to Market Entry
Table 43. RNA Interference (RNAi)-Based Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 44. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 45. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Share by Type (2018-2023)
Table 46. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 47. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023)
Table 48. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 49. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 50. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 51. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 52. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 53. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 54. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 55. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 58. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 59. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 60. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 61. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 62. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 63. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 64. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 65. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 66. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 67. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 68. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 69. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 70. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 71. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 72. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 74. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 75. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 76. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 77. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 78. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 79. RNA Interference (RNAi)-Based Therapeutics Raw Material
Table 80. Key Suppliers of RNA Interference (RNAi)-Based Therapeutics Raw Materials
LIST OF FIGURE
s
Figure 1. RNA Interference (RNAi)-Based Therapeutics Picture
Figure 2. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. siRNA
Figure 5. miRNA
Figure 6. shRNA
Figure 7. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application in 2022
Figure 9. AHP Picture
Figure 10. hATTR Picture
Figure 11. Other Picture
Figure 12. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market RNA Interference (RNAi)-Based Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 16. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Region in 2022
Figure 17. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. Global RNA Interference (RNAi)-Based Therapeutics Revenue Share by Players in 2022
Figure 23. RNA Interference (RNAi)-Based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players RNA Interference (RNAi)-Based Therapeutics Market Share in 2022
Figure 25. Global Top 6 Players RNA Interference (RNAi)-Based Therapeutics Market Share in 2022
Figure 26. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Share by Type (2018-2023)
Figure 27. Global RNA Interference (RNAi)-Based Therapeutics Market Share Forecast by Type (2024-2029)
Figure 28. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Share by Application (2018-2023)
Figure 29. Global RNA Interference (RNAi)-Based Therapeutics Market Share Forecast by Application (2024-2029)
Figure 30. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 31. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 32. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 33. United States RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 37. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 38. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. France RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 45. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 46. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 47. China RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. India RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 53. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 54. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 55. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 59. Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 60. Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 64. RNA Interference (RNAi)-Based Therapeutics Market Drivers
Figure 65. RNA Interference (RNAi)-Based Therapeutics Market Restraints
Figure 66. RNA Interference (RNAi)-Based Therapeutics Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of RNA Interference (RNAi)-Based Therapeutics in 2022
Figure 69. Manufacturing Process Analysis of RNA Interference (RNAi)-Based Therapeutics
Figure 70. RNA Interference (RNAi)-Based Therapeutics Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Table 1. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Alnylam Company Information, Head Office, and Major Competitors
Table 6. Alnylam Major Business
Table 7. Alnylam RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 8. Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Alnylam Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 13. Novartis RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Sylentis Company Information, Head Office, and Major Competitors
Table 16. Sylentis Major Business
Table 17. Sylentis RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 18. Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Sylentis Recent Developments and Future Plans
Table 20. Arrowhead Company Information, Head Office, and Major Competitors
Table 21. Arrowhead Major Business
Table 22. Arrowhead RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 23. Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Arrowhead Recent Developments and Future Plans
Table 25. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 26. Silence Therapeutics Major Business
Table 27. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 28. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Silence Therapeutics Recent Developments and Future Plans
Table 30. Dicerna Company Information, Head Office, and Major Competitors
Table 31. Dicerna Major Business
Table 32. Dicerna RNA Interference (RNAi)-Based Therapeutics Product and Solutions
Table 33. Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Dicerna Recent Developments and Future Plans
Table 35. Global RNA Interference (RNAi)-Based Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 36. Global RNA Interference (RNAi)-Based Therapeutics Revenue Share by Players (2018-2023)
Table 37. Breakdown of RNA Interference (RNAi)-Based Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 38. Market Position of Players in RNA Interference (RNAi)-Based Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 39. Head Office of Key RNA Interference (RNAi)-Based Therapeutics Players
Table 40. RNA Interference (RNAi)-Based Therapeutics Market: Company Product Type Footprint
Table 41. RNA Interference (RNAi)-Based Therapeutics Market: Company Product Application Footprint
Table 42. RNA Interference (RNAi)-Based Therapeutics New Market Entrants and Barriers to Market Entry
Table 43. RNA Interference (RNAi)-Based Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 44. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 45. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Share by Type (2018-2023)
Table 46. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 47. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023)
Table 48. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 49. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 50. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 51. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 52. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 53. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 54. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 55. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 58. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 59. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 60. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 61. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 62. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 63. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 64. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 65. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 66. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 67. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 68. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 69. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 70. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 71. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 72. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 74. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 75. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 76. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 77. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 78. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 79. RNA Interference (RNAi)-Based Therapeutics Raw Material
Table 80. Key Suppliers of RNA Interference (RNAi)-Based Therapeutics Raw Materials
LIST OF FIGURE
s
Figure 1. RNA Interference (RNAi)-Based Therapeutics Picture
Figure 2. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. siRNA
Figure 5. miRNA
Figure 6. shRNA
Figure 7. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application in 2022
Figure 9. AHP Picture
Figure 10. hATTR Picture
Figure 11. Other Picture
Figure 12. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market RNA Interference (RNAi)-Based Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 16. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Region in 2022
Figure 17. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. Global RNA Interference (RNAi)-Based Therapeutics Revenue Share by Players in 2022
Figure 23. RNA Interference (RNAi)-Based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players RNA Interference (RNAi)-Based Therapeutics Market Share in 2022
Figure 25. Global Top 6 Players RNA Interference (RNAi)-Based Therapeutics Market Share in 2022
Figure 26. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Share by Type (2018-2023)
Figure 27. Global RNA Interference (RNAi)-Based Therapeutics Market Share Forecast by Type (2024-2029)
Figure 28. Global RNA Interference (RNAi)-Based Therapeutics Consumption Value Share by Application (2018-2023)
Figure 29. Global RNA Interference (RNAi)-Based Therapeutics Market Share Forecast by Application (2024-2029)
Figure 30. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 31. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 32. North America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 33. United States RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 37. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 38. Europe RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. France RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 45. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 46. Asia-Pacific RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 47. China RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. India RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 53. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 54. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 55. South America RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 59. Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 60. Middle East and Africa RNA Interference (RNAi)-Based Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE RNA Interference (RNAi)-Based Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 64. RNA Interference (RNAi)-Based Therapeutics Market Drivers
Figure 65. RNA Interference (RNAi)-Based Therapeutics Market Restraints
Figure 66. RNA Interference (RNAi)-Based Therapeutics Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of RNA Interference (RNAi)-Based Therapeutics in 2022
Figure 69. Manufacturing Process Analysis of RNA Interference (RNAi)-Based Therapeutics
Figure 70. RNA Interference (RNAi)-Based Therapeutics Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
